Company profile
Nammi Therapeutics Inc
Privately held: no public share price (Small clinical-stage biotech sponsoring a single registered MM trial; no public listing found via WebSearch. Recorded private per default for an unlisted, venture-stage company rather than guessed public. Sources: https://clinicaltrials.gov/study/NCT06582017 Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | CD138 (Syndecan-1)Biologic — subtype unspecified | Multiple Myeloma |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.